Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily G Moser

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Diabetes Technology & Therapeutics|June 15, 2011
How basal insulin analogs have changed diabetes careSatish K Garg, Emily G Moser
Diabetes Research and Clinical Practice|March 3, 2012
Emerging diabetes therapies and technologiesEmily G Moser, Audrey A Morris, Satish K Garg
Journal of the American Association for Laboratory Animal Science : JAALAS|March 8, 2014
Lack of fear response in mice (Mus musculus) exposed to human urine odorGermain F Rivard, Emily G Moser, Steven P D'Ambrose, et al.
Endocrinology and Metabolism Clinics of North America|May 12, 2012
Intensive insulin therapy in patients with type 1 diabetes mellitusSean M Switzer, Emily G Moser, Briana E Rockler, et al.
Diabetes Technology & Therapeutics|June 22, 2013
A primary care perspective on the use of continuous glucose monitoring in clinical practiceManisha Bhide, Jessica M S Grey, Emily G Moser, et al.
Diabetes Technology & Therapeutics|August 23, 2013
The future of basal insulinViral N Shah, Emily G Moser, Aaron Blau, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 29, 2012
Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trialSatish K Garg, Emily G Moser, Bruce W Bode, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Diabetes Technology & Therapeutics|June 15, 2011
How basal insulin analogs have changed diabetes careSatish K Garg, Emily G Moser
Diabetes Research and Clinical Practice|March 3, 2012
Emerging diabetes therapies and technologiesEmily G Moser, Audrey A Morris, Satish K Garg
Journal of the American Association for Laboratory Animal Science : JAALAS|March 8, 2014
Lack of fear response in mice (Mus musculus) exposed to human urine odorGermain F Rivard, Emily G Moser, Steven P D'Ambrose, et al.
Endocrinology and Metabolism Clinics of North America|May 12, 2012
Intensive insulin therapy in patients with type 1 diabetes mellitusSean M Switzer, Emily G Moser, Briana E Rockler, et al.
Diabetes Technology & Therapeutics|June 22, 2013
A primary care perspective on the use of continuous glucose monitoring in clinical practiceManisha Bhide, Jessica M S Grey, Emily G Moser, et al.
Diabetes Technology & Therapeutics|August 23, 2013
The future of basal insulinViral N Shah, Emily G Moser, Aaron Blau, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 29, 2012
Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trialSatish K Garg, Emily G Moser, Bruce W Bode, et al.
Pageof 1